ARG-007 / Argenica Therap - LARVOL DELTA

A Phase II, Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients (ANZCTR) - P2 | N=92 | Active, not recruiting | Sponsor: Argenica Therapeutics Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Ischemic stroke

A Phase II, Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients (ANZCTR) - P2 | N=92 | Recruiting | Sponsor: Argenica Therapeutics Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024

Enrollment open • Trial initiation date • Cardiovascular • Ischemic stroke

A Phase II, Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients (ANZCTR) - P2 | N=92 | Not yet recruiting | Sponsor: Argenica Therapeutics Ltd

New P2 trial • Cardiovascular • Ischemic stroke

A study to investigate ARG-007 in Healthy Volunteers (ANZCTR) - P1 | N=32 | Completed | Sponsor: Argenica Therapeutics Ltd. | Initiation date: Sep 2000 ➔ Sep 2022

Trial initiation date • Cardiovascular • CXCL8 • IFNG • IL10 • IL4 • IL6 • TNFA